alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
# C_2014102EN.01001401.xml

| 7.4.2014 | EN | Official Journal of the European Union | C 102/14 |
| --- | --- | --- | --- |

7.4.2014

EN

Official Journal of the European Union

C 102/14

---

Request for a preliminary ruling from the Juzgado de Primera Instancia (Spain) lodged on 10 January 2014 — Unnim Banc, S.A. v Diego Fernández Gabarro and Others

(Case C-8/14)

2014/C 102/18

Language of the case: Spanish

Referring court

Referring court

Juzgado de Primera Instancia

Parties to the main proceedings

Parties to the main proceedings

Applicant: Unnim Banc, S.A.

Applicant:

Defendants: Diego Fernández Gabarro, Pedro Penalva López and Clara López Durán

Defendants:

Question referred

Question referred

Is the limitation period of one month provided for by Law 1/2013 on the protection of mortgagors, restructuring of debt and social rent contrary to the terms of Articles 6 and 7 of Directive 93/13/EEC  (1)?

1

---

(1)  Council Directive 93/13/EEC of 5 April 1993 on unfair terms in consumer contracts

1

OJ 1993 L 95, p. 29.

---
Exhibit 23.1



CONSENT OF INDEPENDENT REGISTERED PUBLIC
ACCOUNTING FIRM



We consent to the incorporation by reference in the Registration
Statement (Form S-3) pertaining to First Defiance Financial Corp.’s registration of common and preferred stock; Registration
Statement (Form S-8) pertaining to the First Defiance Financial Corp. 2011 Equity Incentive; and Registration Statement (Form S-8)
pertaining to First Defiance Financial Corp. Employee Investment Plan, of our report dated February 28, 2013 on the consolidated
financial statements and the effectiveness of internal control over financial reporting of First Defiance Financial Corp. which
report is included in Form 10-K for First Defiance Financial Corp. for the year ended December 31, 2012.



| | /s/ Crowe Horwath LLP
| | ---------------------
| |                      
| | Crowe Horwath LLP    



South Bend, Indiana

February 28, 2013
<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE FORM
10-Q FOR THE QUARTER ENDED SEPTEMBER 30, 1998 AND IS QUALIFIED IN ITS ENTIRETY
BY REFERENCE TO SUCH FINANCIAL STATEMENTS.
</LEGEND>
<MULTIPLIER> 1,000
<CURRENCY> U.S. DOLLARS
       
<S>                             <C>
<PERIOD-TYPE>                   6-MOS
<FISCAL-YEAR-END>                          DEC-31-1998
<PERIOD-START>                             JAN-01-1998
<PERIOD-END>                               SEP-30-1998
<EXCHANGE-RATE>                                      1
<CASH>                                          33,445
<SECURITIES>                                    36,754
<RECEIVABLES>                                   14,509
<ALLOWANCES>                                       938
<INVENTORY>                                     14,121
<CURRENT-ASSETS>                               101,793
<PP&E>                                          23,693
<DEPRECIATION>                                  14,538
<TOTAL-ASSETS>                                 144,359
<CURRENT-LIABILITIES>                           21,700
<BONDS>                                          1,445
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                           314
<OTHER-SE>                                     120,900
<TOTAL-LIABILITY-AND-EQUITY>                   144,359
<SALES>                                         67,520
<TOTAL-REVENUES>                                67,520
<CGS>                                           40,457
<TOTAL-COSTS>                                   68,060
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                   166
<INTEREST-EXPENSE>                                 630
<INCOME-PRETAX>                                 36,331
<INCOME-TAX>                                     4,952
<INCOME-CONTINUING>                             31,379
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                    31,379
<EPS-PRIMARY>                                     1.00
<EPS-DILUTED>                                     1.00
        

</TABLE>
Consent
      of Independent Auditors





The
      Board
      of Directors


Preferred
      Voice, Inc.





We
      hereby
      consent to the use in the Form 10-KSB filing of our report dated May 24, 2006,
      relating to the balance sheet of Preferred Voice, Inc. as of March 31, 2006,
      and
      the related statements of operations, changes in shareholders’ equity, and cash
      flows for the year ended March 31, 2006, which are contained in that
      filing.


/s/
        Philip Vogel & Co. PC




Dallas,
      Texas


July
      13,
      2006
#### § 801.6 Medical devices; misleading statements.

Among representations in the labeling of a device which render such device misbranded is a false or misleading representation with respect to another device or a drug or food or cosmetic.
In the

Court of Appeals

Second Appellate District of Texas

at Fort Worth ___________________________

No. 02-21-00256-CV

___________________________

Original Proceeding

325th District Court of Tarrant County, Texas

Trial Court No. 325-692724-20

Before Wallach, Birdwell, and Bassel, JJ.

Per Curiam Memorandum Opinion

IN RE J.B., Relator
2

MEMORANDUM OPINION

The court has considered relator’s petition for writ of mandamus, the record, 

real party in interest’s response, and relator’s reply and is of the opinion that relief 

should be denied. Accordingly, relator’s petition for writ of mandamus is denied and 

our August 24, 2021 order to stay is hereby vacated.

Per Curiam

Delivered: September 24, 2021
Exhibit 11.1


 BAB HOLDINGS, INC.
 CALCULATION OF EARNINGS PER SHARE
 YEARS ENDED NOVEMBER 30, 1996 AND 1995




                                                   1996             1995
                                             ---------------    ---------------


PRIMARY

     Net Loss                                    (320,844.00)       (435,760.00)
     Less pref. stock dividend                          --            (4,000.00)
        Net loss applicable to                ---------------    ---------------
           common shareholders                   (320,844.00)       (439,760.00)
                                              ===============    ===============

     Weighted average share outstanding            7,366,645          3,382,916

     Net loss per common share               $       (0.0436)   $       (0.1300)




FULLY DILUTED

     Net loss                                    (320,844.00)       (435,760.00)
     Less pref. stock dividend                          --            (4,000.00)
     Add back "as if" stock dividend                    --             4,000.00
     Bond interest exp. on "as if" conv               566.00           6,525.00
                                             ===============    ===============
        Net loss applicable to
           common shareholders                   (320,278.00)       (429,235.00)
                                             ===============    ===============

     Weighted average shares outstanding           7,420,538          3,560,257

     Net  loss per common share,
        fully diluted                        $       (0.0432)   $       (0.1206)
<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
This schedule contains summary financial information extracted from the
Consolidated Statement of Financial Conditoin at December 31, 1999 Audited
and the Consolidated Statement of Income for the year ended December 31, 1999
Audited and is qualified in its entirety by reference to such financial
statements.
</LEGEND>

<S>                             <C>
<PERIOD-TYPE>                   YEAR
<FISCAL-YEAR-END>                          DEC-31-1999
<PERIOD-END>                               DEC-31-1999
<CASH>                                       3,377,067
<SECURITIES>                                         0
<RECEIVABLES>                                   95,222
<ALLOWANCES>                                    43,000
<INVENTORY>                                    356,211
<CURRENT-ASSETS>                             4,367,323
<PP&E>                                         519,721
<DEPRECIATION>                                 125,563
<TOTAL-ASSETS>                               5,670,245
<CURRENT-LIABILITIES>                        1,149,129
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                       168,359
<OTHER-SE>                                   4,352,758
<TOTAL-LIABILITY-AND-EQUITY>                 5,670,245
<SALES>                                      1,368,513
<TOTAL-REVENUES>                             1,722,005
<CGS>                                        1,410,731
<TOTAL-COSTS>                                1,410,731
<OTHER-EXPENSES>                            12,604,929
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                  28
<INCOME-PRETAX>                           (12,301,718)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                                  0
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                              (12,301,718)
<EPS-BASIC>                                     (0.77)
<EPS-DILUTED>                                   (0.77)


</TABLE>
<PAGE>   1

                                  EXHIBIT 24.2

                      POWER OF ATTORNEY OF ROBERT T. KNIGHT


         KNOW ALL MEN BY THESE PRESENTS, that the undersigned, Robert T. Knight,
hereby constitutes and appoints Peter A. Allen or Gordon A. Gardiner his true
and lawful attorney-in-fact and agent, for him and his name, place and stead, in
any and all capacities, to sign the Registration Statement on Form S-3 of Data
Dimensions, Inc., a Delaware corporation, and any amendments or supplements
thereto, and to file this Power of Attorney and the Form S-3, with all exhibits
thereto, and other documents in connection therewith with the Securities and
Exchange Commission and the Nasdaq National Market System, granting unto said
attorney-in-fact and agent full power and authority to do and perform each and
every thing requisite and necessary to be done in and about the premises, as
fully to all intents and purposes as he might or could do in person, hereby
ratifying and confirming all that said attorney-in-fact and agent may do or
cause to be done by virtue hereof.

         Dated this 4th day of March, 1999.

Signature:


/s/ Robert T. Knight
-------------------------------
Robert T. Knight



                                     III-6
<TABLE> <S> <C>

<PAGE>
<ARTICLE> 5
<RESTATED> 
       
<S>                             <C>                     <C>
<PERIOD-TYPE>                   YEAR                   YEAR
<FISCAL-YEAR-END>                          DEC-31-1998             DEC-31-1997
<PERIOD-START>                             JAN-01-1998             JAN-01-1997
<PERIOD-END>                               DEC-31-1998             DEC-31-1997
<CASH>                                      14,291,000               6,396,000
<SECURITIES>                                22,603,000               1,359,000
<RECEIVABLES>                               10,115,000              10,489,000
<ALLOWANCES>                                   768,000               1,224,000
<INVENTORY>                                          0                       0
<CURRENT-ASSETS>                            59,207,000              25,775,000
<PP&E>                                       5,896,000               5,102,000
<DEPRECIATION>                               4,427,000               3,164,000
<TOTAL-ASSETS>                              63,613,000              30,525,000
<CURRENT-LIABILITIES>                       13,665,000              14,366,000
<BONDS>                                              0                       0
<PREFERRED-MANDATORY>                                0                       0
<PREFERRED>                                          0                       0
<COMMON>                                       135,000                 134,000
<OTHER-SE>                                  49,747,000              14,083,000
<TOTAL-LIABILITY-AND-EQUITY>                63,613,000              30,525,000
<SALES>                                      5,822,000               9,213,000
<TOTAL-REVENUES>                            28,941,000              32,161,000
<CGS>                                        1,957,000               2,749,000
<TOTAL-COSTS>                               19,540,000              18,803,000
<OTHER-EXPENSES>                            16,934,000              32,420,000
<LOSS-PROVISION>                             1,257,000               1,055,000
<INTEREST-EXPENSE>                           (496,000)                 (4,000)
<INCOME-PRETAX>                            (8,294,000)            (20,113,000)
<INCOME-TAX>                                 (803,000)               (877,000)
<INCOME-CONTINUING>                        (7,491,000)            (19,236,000)
<DISCONTINUED>                              41,642,000                 742,000
<EXTRAORDINARY>                                      0                       0
<CHANGES>                                            0                       0
<NET-INCOME>                                34,151,000            (18,494,000)
<EPS-PRIMARY>                                     2.53                  (1.40)
<EPS-DILUTED>                                     2.53                  (1.40)
        

</TABLE>
EXHIBIT 23

                         Independent Auditors' Consent



<PAGE>










                                   Exhibit 23

                          INDEPENDENT AUDITORS' CONSENT

     We consent to the incorporation by reference in the Registration  Statement
of Klamath  First  Bancorp,  Inc. on Form S-8 (File No.  333-4002) of our report
dated  October 29, 1999,  on the  financial  statements  appearing in the Annual
Report to  stockholders  of  Klamath  First  Bancorp,  Inc.  for the year  ended
September 30, 1999.


/s/ DELOITTE & TOUCHE LLP

Portland, Oregon
December 28, 1999

<PAGE>
Exhibit 23 

 

**Consent of Independent Auditors**

 

The Board of Directors 

Preferred Voice, Inc. 

 

We consent to the incorporation by reference in the Registration Statements (Form S-3 FileNo. 333-99879 and Form S-8 No. 333-56728 and 333-82150) pertaining to Preferred Voice, Inc. of our report, dated May 25, 2004, with respect to the consolidated financial statements of Preferred Voice, Inc. included in this Annual Report (Form10-KSB) for the year ended March 31, 2004. 

 

 

Dallas, Texas 

 

July 8, 2004
§ 520.980 Fluoxetine. ( a ) *Specifications.* Each chewable tablet contains 8, 16, 32, or 64 milligrams (mg) fluoxetine hydrochloride.
( b ) *Sponsor.* See No. 055246 in § 510.600 of this chapter.
( c ) *Conditions of use in dogs* — ( 1 ) *Amount.* 1 to 2 mg per kilogram body weight once daily.
( 2 ) *Indications for use.* For the treatment of canine separation anxiety in conjunction with a behavior modification plan.
( 3 ) *Limitations.* Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[72 FR 6463, Feb. 12, 2007, as amended at 79 FR 74020, Dec. 15, 2014; 82 FR 21690, May 10, 2017]
<TABLE> <S> <C>

<PAGE>
<ARTICLE> 5
<MULTIPLIER> 1,000

<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                          MAR-31-2001
<PERIOD-START>                             APR-01-2000
<PERIOD-END>                               JUL-02-2000
<CASH>                                          16,529
<SECURITIES>                                         0
<RECEIVABLES>                                  417,606
<ALLOWANCES>                                    62,102
<INVENTORY>                                    402,700
<CURRENT-ASSETS>                               812,612
<PP&E>                                         780,840
<DEPRECIATION>                                 351,880
<TOTAL-ASSETS>                               1,850,718
<CURRENT-LIABILITIES>                          571,444
<BONDS>                                      1,085,617
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                           215
<OTHER-SE>                                    (74,884)
<TOTAL-LIABILITY-AND-EQUITY>                 1,850,718
<SALES>                                        465,800
<TOTAL-REVENUES>                               465,800
<CGS>                                          342,362
<TOTAL-COSTS>                                  342,362
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                 1,611
<INTEREST-EXPENSE>                              24,687
<INCOME-PRETAX>                               (12,205)
<INCOME-TAX>                                   (3,198)
<INCOME-CONTINUING>                            (9,355)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                   (9,355)
<EPS-BASIC>                                     (0.44)
<EPS-DILUTED>                                   (0.44)


</TABLE>
<TABLE> <S> <C>

<ARTICLE> 5
       
<S>                             <C>
<PERIOD-TYPE>                   YEAR
<FISCAL-YEAR-END>                               DEC-31-1996
<PERIOD-START>                                  JAN-01-1996
<PERIOD-END>                                    DEC-31-1996
<CASH>                                                4,038
<SECURITIES>                                              0
<RECEIVABLES>                                         2,102
<ALLOWANCES>                                            394
<INVENTORY>                                          10,689
<CURRENT-ASSETS>                                     18,732 
<PP&E>                                               19,261 
<DEPRECIATION>                                        9,432 
<TOTAL-ASSETS>                                       30,043
<CURRENT-LIABILITIES>                                 7,918 
<BONDS>                                               1,164   
<PREFERRED-MANDATORY>                                     0
<PREFERRED>                                               0
<COMMON>                                                 41
<OTHER-SE>                                           20,701
<TOTAL-LIABILITY-AND-EQUITY>                         30,034
<SALES>                                              46,635
<TOTAL-REVENUES>                                     46,635
<CGS>                                                35,755
<TOTAL-COSTS>                                        35,755
<OTHER-EXPENSES>                                          0
<LOSS-PROVISION>                                        205
<INTEREST-EXPENSE>                                      133
<INCOME-PRETAX>                                       2,168
<INCOME-TAX>                                            662
<INCOME-CONTINUING>                                   1,506
<DISCONTINUED>                                            0
<EXTRAORDINARY>                                           0
<CHANGES>                                                 0
<NET-INCOME>                                          1,506
<EPS-PRIMARY>                                           .37
<EPS-DILUTED>                                           .37
        

</TABLE>
§ 610.9 Equivalent methods and processes. Modification of any particular test method or manufacturing process or the conditions under which it is conducted as required in this part or in the additional standards for specific biological products in parts 620 through 680 of this chapter shall be permitted only under the following conditions: ( a ) The applicant presents evidence, in the form of a license application, or a supplement to the application submitted in accordance with § 601.12(b) or (c), demonstrating that the modification will provide assurances of the safety, purity, potency, and effectiveness of the biological product equal to or greater than the assurances provided by the method or process specified in the general standards or additional standards for the biological product; and
( b ) Approval of the modification is received in writing from the Director, Center for Biologics Evaluation and Research or the Director, Center for Drug Evaluation and Research.
[62 FR 39903, July 24, 1997, as amended at 70 FR 14984, Mar. 24, 2005]
# L_2019085EN.01001801.xml

| 27.3.2019 | EN | Official Journal of the European Union | L 85/18 |
| --- | --- | --- | --- |

27.3.2019

EN

Official Journal of the European Union

L 85/18

---

EUROPEAN COUNCIL DECISION (EU) 2019/508

of 22 March 2019

appointing a member of the Executive Board of the European Central Bank

THE EUROPEAN COUNCIL,

Having regard to the Treaty on the Functioning of the European Union, and in particular Article 283(2),

Having regard to the recommendation of the Council of the European Union (1),

Having regard to the opinion of the European Parliament (2),

Having regard to the opinion of the Governing Council of the European Central Bank (3),

Whereas:

| (1) | The term of office of Mr Peter PRAET, member of the Executive Board of the European Central Bank, expires on 31 May 2019. It is therefore necessary to appoint a new member of the Executive Board of the European Central Bank. |
| --- | --- |

(1)

The term of office of Mr Peter PRAET, member of the Executive Board of the European Central Bank, expires on 31 May 2019. It is therefore necessary to appoint a new member of the Executive Board of the European Central Bank.

| (2) | The European Council wishes to appoint Mr Philip R. LANE, who, in its view, fulfils all the requirements set out in Article 283(2) of the Treaty, |
| --- | --- |

(2)

The European Council wishes to appoint Mr Philip R. LANE, who, in its view, fulfils all the requirements set out in Article 283(2) of the Treaty,

HAS ADOPTED THIS DECISION:

Article 1

Mr Philip R. LANE is hereby appointed a member of the Executive Board of the European Central Bank for a term of office of eight years as from 1 June 2019.

Article 2

This Decision shall enter into force on the date of its adoption.

Done at Brussels, 22 March 2019.

For the European Council

The President

D. TUSK

---

(1)  
  OJ C 60, 15.2.2019, p. 1.

1

(2)  Opinion delivered on 14 March 2019 (not yet published in the Official Journal).

2

(3)  Opinion delivered on 6 March 2019 (not yet published in the Official Journal).

3

---